Physician profile
Michael E Feldman
NPI 1184618761
$8,449.82
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,337 · 2020: $2,050 · 2021: $7.64 · 2022: $16.33 · 2023: $13.60 · 2024: $24.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.50 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.50 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $7,255.09 | 2019-2020 | |
| Baxter Healthcare | $900.00 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $134.85 | 2020 | |
| Vifor Pharma, INC. | $43.45 | 2019-2020 | |
| Amgen INC. | $24.50 | 2024 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $17.14 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.53 | 2019 | |
| Boston Scientific Corporation | $16.51 | 2019 | |
| Travere Therapeutics, INC. | $15.64 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Horizon Therapeutics Plc | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.